Novo Nordisk (NYSE: NVO) Shares Fell Approximately 6% Thursday August 13, 2026 on Broker Downgrade Citing Continued Franchise-Gap Pressure From Eli Lilly's (NYSE: LLY) Tirzepatide Franchise and the CagriSema Head-to-Head Miss Against Tirzepatide (23.0% Versus 25.5% Weight Loss at 84 Weeks in the REDEFINE 4 Head-to-Head Phase 3 Trial); The August 4 H1 2026 Earnings Release Raised Full-Year 2026 Sales Guidance to Down 3% From Prior Down 8% Midpoint but the Broader Investor Narrative Continues to Focus on Novo's Ability to Defend GLP-1 Franchise Economics Against Eli Lilly's Q2 2026 $23 Billion Revenue Blowout (+48% YoY), Foundayo (Orforglipron) $98 Million First Commercial Quarter, and Retatrutide's 28.7% Phase 3 TRIUMPH-4 Weight Loss Result
Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.